Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized, Partially Blinded, Phase 2 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB

NCT03828201 is registered in ClinicalTrials.gov with Boston University as lead sponsor.

NCT NCT03828201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03828201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized, Partially Blinded, Phase 2 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB
Lead sponsor
Boston University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 7, 2022
Completion date
May 31, 2027
Enrollment
271 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, multidrug-resistant